Objective:To explore the impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer (NSCLC) .Methods:The retrospective analysis of clinical data from 121 patients diagnosed with advanced NSCLC who were admitted to the Second Affiliated Hospital of Xingtai Medical College from August 2021 to January 2023 was conducted. These patients were divided into a control group ( n=57) and an observation group ( n=64) based on the designated treatment protocol. Specifically, individuals in the control group received standard chemotherapy (cisplatin+paclitaxel), while those in the observation group underwent penpilimab therapy in conjunction with conventional chemotherapy. The comparative assessment encompassed short-term clinical efficacy, quality of life, immune function parameters, angiogenic factors [including endostatin, insulin-like growth factor 1 (IGF-1), and vascular endothelial growth factor (VEGF) ], circulating endothelial cells, and adverse reactions within the two groups. Results:After 6 courses of treatment, the objective response rate [67.19% (43/64) vs. 49.12% (28/57) ] and disease control rate [87.50% (56/64) vs. 70.18% (40/57) ] in observation group were higher than those in control group, with statistically significant differences ( χ2=4.06, P=0.044; χ2=5.52, P=0.019). The quality of life score of observation group [ (56.77±6.81) points] was significantly higher than that of control group [ (47.73±8.23) points], with a statistically significant difference ( t=6.61, P<0.001) ; The T cell subgroup CD3 + levels [ (63.59±9.00) % vs. (53.06±8.80%), t=6.49, P<0.001], CD4 + levels [ (46.54±8.20) % vs. (30.74±7.32) %, t=11.13, P<0.001] and CD4 +/CD8 + ratio (1.90±0.36 vs. 1.21±0.28, t=11.66, P<0.001) in observation group were significantly higher than those in control group, with statistically significant differences; Endostatin in observation group [ (48.99±3.43) μmol/L] was significantly higher than that in control group [ (31.35±3.87) μmol/L], with a statistically significant difference ( t=26.58, P<0.001), IGF-1 [ (102.31±20.35) μg/L vs. (134.98±19.02) μg/L] and VEGF [ (31.70±4.32) pg/ml vs. (58.71±5.99) pg/ml] were significantly lower in observation group than those in control group, with statistically significant differences ( t=18.73, P<0.001; t=28.14, P<0.001). The number of circulating endothelial cells in observation group [ (58.77±10.03) /ml] was significantly lower than that in control group [ (87.01±8.01) /ml], with a statistically significant difference ( t=17.20, P<0.001). During treatment, there were no statistically significant differences in the incidence of gastrointestinal reaction ( χ2=0.01, P=0.908), leukopenia ( χ2=0.64, P=0.424), thrombocytopenia ( χ2=0.28, P=0.597), anemia ( χ2=1.66, P=0.197), nephrotoxicity ( χ2=0.64, P=0.424), skin rash ( χ2=1.33, P=0.249) between the two groups. Conclusion:The combination therapy of pembrolizumab and chemotherapy for the treatment of advanced NSCLC has demonstrated noteworthy effectiveness. This regimen has the potential to enhance patients' immune functionality, ameliorate their overall quality of life, suppress angiogenesis, and exhibits a commendable profile of safety and reliability.

Objective To explore the relationship between blood uric acid levels and non-alcoholic fatty liver disease in patients with type H hypertension.Methods The clinical data of 284 patients with type H hyper-tension admitted to the Cardiovascular Department,Xianyang Hospital,Yan'an University in 2022 were collected and retrospectively reviewed.The patients were divided into NAFLD group(n=88)and normal group(n=196)according to whether they had NAFLD.The general information and laboratory indicators were compared between the two groups.Multivariate logistic regression analysis was conducted to explore the influencing factors of NAFLD in H-type hypertension patients.The draw ROC curves were plotted to observe the role of SUA in predicting NAFLD and select the optimal cutoff value based on the maximum Youden index.Results The NAFLD group demonstrated higher levels in body mass index,systolic blood pressure,diastolic blood pressure,total cholesterol,triglycerides,low-density lipoprotein cholesterol,SUA,γ-Glutamyl transpeptidase and alanine aminotransferase compared to the normal group,but significantly lower levels at age and high-density lipoprotein cholesterol(P＜0.05).The multivariate logistic regression analysis showed that elevated levels of BMI(OR=1.173,95%CI:1.066～1.291),SUA(OR=1.005,95%CI:1.001～1.010),and TG(OR=1.929,95%CI:1.042～3.574)were risk factors for NAFLD in patients with type H hypertension(P＜0.05).The ROC curves showed that the area under the curve(AUC)of SUA,TG,BMI,and their combination were 0.709,0.707,0.750,and 0.796,respectively.Conclusion type H hypertensive NAFLD patients have high levels of BMI,SUA,TG compared to non-NAFLD patients.Elevated SUA is a risk factor for type H hypertensive NAFLD patients,with SUA＞337 μmol/L as a significant value for predicting NAFLD.